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Abstract: Diets high in sugar or fat are associated with multiple health conditions, 
including binge eating disorder (BED). BED affects approximately 2% of the US adult 
population, and occurs more frequently in females. It is important to develop animal 
models of palatable food consumption, food seeking, and voluntary physical activity that 
may have relevance for BED and other conditions associated with excessive food 
intake. The catecholamine uptake blocker and d-amphetamine prodrug 
lisdexamfetamine (LDX) is used to treat BED. The present experiments studied the 
effect of LDX on food intake and two effort-based choice tasks in female Wistar rats. In 
experiment one, three groups of rats received different food exposure conditions in the 
home cage randomly spread over several weeks: the chocolate exposure group (CE; 
brief access of chocolate and additional lab chow, n=15), a lab chow exposure (LChE) 
group was given additional access to lab chow (n=8), and a third group was given 
empty food dishes (n=7). In tests of food intake under non-restricted conditions, LDX 
(0.1875-1.5 mg/kg IP) significantly reduced intake of both chocolate and chow in the CE 
group. In the LChE group, there was a trend towards reduced chow intake induced by 
LDX. All rats were trained on a Progressive Ratio/chow feeding choice task, in which 
they had a choice between working for high carbohydrate chocolate flavored pellets by 
lever pressing vs. approaching and consuming a concurrently available lab chow. The 
LChE group and the empty food dish group were combined to create one control group 
(n=15). There was a significant overall dose-related suppressive effect of LDX on lever 
pressing but no group difference, and no dose x group interaction. LDX significantly 
decreased chow intake in the CE group, but not in the control group. In Experiment two, 
rats (n=8) were given brief access of chocolate in the home cage randomly spread over 
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several weeks. They were then trained on a novel T-Maze task in which they had a 
choice to eat freely available chocolate or run on a running wheel. LDX (0.09375-1.5 
mg/kg IP) significantly reduced intake of chocolate, and a trend towards reduced 
running wheel activity was seen. In conclusion, LDX affected both food intake, food-
reinforced operant behavior, and running wheel activity.  
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Introduction 
Disordered eating, such as what is seen in anorexia nervosa, bulimia nervosa, 
and Binge Eating Disorder (BED), is associated with both physical and psychological 
disorders. Individuals with eating disorders have increased risks for cardiovascular 
problems, neurological dysfunction, decreased immune function and increases in 
anxiety (Johnson et al. 2002). This can lead to increased levels of diabetes and 
psychiatric disorders later in life (Johnson et al. 2001). Mortality due to eating disorders 
is very high in part to factors such as increased rates of smoking, alcoholism and 
suicide within the population (Herzog et al. 2000). Implications on reproductive health in 
individuals with a history of EDs have also started to come to light, including infertility 
and increased risk of miscarriage (O’Brien et al. 2017). 
With the release of the DSM-V in 2013, BED was recognized as one of three 
specified feeding and eating disorders. Before this time, people with BED were 
considered as having an “eating disorder not otherwise specified.” BED’s representation 
as a distinct category distinguishes it from overeating, which is a major public health 
concern today, but does not encompass all of the psychological symptoms associated 
with BED such as the feeling of a lack of control in food consumption. This leads an 
individual to consume large amounts of food more rapidly than normal in a short period 
of time, typically consuming food until uncomfortably full, even if the person is not 
hungry. These episodes occur at least once a week during a 3 month period, and 
individuals report being extremely distraught over them (DSM-V; APA 2013). A survey 
completed by the World Health Organization (WHO) conducted across 14 different 
countries found BED to have a lifetime prevalence rate of 1.4%, with a typical onset 
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being in the late teens to early 20’s (Kessler et. al 2013). In the United Sates alone, 
BED has a lifetime and 12-month prevalence rate of 0.85% and 0.44% respectively. 
(Udo & Grilo 2018). Occurrence is higher in women (3.5%) than in men (2.0%) and has 
been shown to be relatively independent of weight but is more common among 
overweight and obese individuals (Bruce and Wilfley 1996, Hudson et al. 2007). Diets 
high in fat and sugar have been linked to increases in obesity, type 2 diabetes, 
hypertension and cardiovascular disease (Guh at el. 2009). 
Treatment outcomes for BED are variable based on the treatment used (Wilson 
2011). Common treatments for BED include both psychological and pharmacological 
interventions. Cognitive behavioral therapy and guided self-help have shown the most 
promise in terms of psychological treatments (Ghaderi et al. 2018). Pharmacologically, 
many classes of drugs have been looked at, including antidepressants such as the 
SSRI fluoxetine (Prozac), anti-obesity, antiepileptic, and anti-addiction medications 
(Ghaderi et al. 2018). The d-amphetamine pro-drug lisdexamfetamine (LDX; Vivanse), a 
common medication for treating attention deficit hyperactivity disorder, was approved for 
the treatment of moderate to severe BED in 2015. As a pro-drug, LDX has a slower on 
set and longer lasting effects (Heal et al. 2013). LDX, due to l-lysine being covalently 
bound to d-amphetamine, is inactive until it is metabolized within the body, more 
specifically within the red blood cells (Pennick 2010, Heal et. al 2013).   
Animal models of binge-like feeding behavior have been developed (Hagan et al. 
2002, Colantuoni 2003, Avena & Hoebel 2003, Rada et al. 2005, Boggiano & Chandler 
2006, Corwin & Wojnicki 2006, Avena et al. 2004, 2006, Heyne et al. 2009; Vickers et 
al. 2015; Smith et al. 2015; Smail-Crevier et al. 2018), which involve induction of 
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excessive eating of a highly palatable food. After inducing chocolate binging behavior in 
rats, Vickers et al. (2015) reported that LDX can reduce chocolate intake in a dose-
dependent manner during binging sessions. Vickers et al. (2015) highlighted the 
effectiveness of LDX at attenuating consumption, but did not look at effort-related 
aspects of food seeking or reinforced behavior. The following experiments were 
intended to address this. 
 
Experiment One: Operant Conditioning 
One characteristic of motivated behavior is that a high degree of effort is often 
expended in order to achieve a goal. Behavioral tasks have been developed to look at 
effort-related aspects of motivated behavior in both humans and animals (Salamone et 
al. 1991, 1994, 2016; Treadway et al. 2009; Randall et al. 2012; Sommer et al. 2014; 
Hosking et al. 2015). These tasks include maze procedures that require high physical 
activity to obtain reinforcers, operant procedures such as progressive ratio (PROG) 
schedules that require increasing levels of work output to obtain reinforcement, and 
effort-based decision making tasks (Salamone et al. 2016). Nasser et al. (2008) studied 
humans with and without a BED diagnosis using a food-reinforced PROG operant task. 
Before the task, subjects were either given water or a drinkable meal. Nasser et al. 
(2008) reported that individuals without BED had a significant reduction in the amount of 
work they were willing to put into achieving their food reward after receiving the meal 
drink, whereas individuals diagnosed with BED did not. These results indicated that 
people with BED are not motivated by hunger.   
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Because it is critical to employ animal models to study phenomena related to 
binge eating on palatable foods, the present experiments studied the effect of LDX on 
food intake and food-reinforced effort-based choice in female Wistar rats. Three groups 
of rats received different food exposure conditions in the home cage randomly spread 
over several weeks: the chocolate exposure group (CE; brief access of chocolate and 
additional lab chow, n=15), a lab chow exposure (LChE) group was given additional 
access to lab chow (n=8), and a third group was given empty food dishes (n=7). 
Chocolate intake in female Wistar rats was studied based upon the Vickers et al. (2015) 
procedure. After having experience with their respective exposure conditions, the rats 
were tested for the effects of LDX on intake of the different foods (chocolate and 
standard lab chow) as well as effort-based choice using the PROG/chow feeding choice 
procedure that has been developed in our laboratory (Randall et al. 2012, 2014, 2015; 
Yohn et al. 2016 a,b,c). With this task, rats had a choice between working for preferred 
high carbohydrate chocolate flavored pellets by lever pressing on the PROG schedule 
vs. approaching and consuming a concurrently available but less preferred lab chow.  
These procedures allowed for investigation of the effects of LDX on food intake as well 
as the tendency to work for food.   
 
Methods 
Animals  
Singly-housed, adult female, Wistar rats (N = 30 Charles River) weighing 
between 226-250 grams on arrival were food restricted to 85% of their free feeding 
weights for 16 weeks allowing for modest growth. Water was available ad libitum. 
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Starting at 17 weeks, rats were given food ad libitum. All animal procedures were 
approved by the Institutional Animal Care and Use Committee. 
 
Operant Training 
Using Med Associates operant chambers (28 × 23 × 23 cm), rats were trained to 
lever press for high carbohydrate pellets on a FR1 schedule for 3 weeks. Training then 
began on the PROG task for 8 weeks (30 min sessions, 5 days a week) after which 
freely available lab chow was placed in the box during their session (PROG/chow 
choice task) to give them an option of either lever pressing for pellets or approaching 
and consuming the lab chow. They remained on the PROG/chow feeding choice task 
for the remainder of the experiment. Rats were weighed prior to each operant task. At 
week 11 of training on the PROG/chow choice task, the rats were transitioned from 
plain high carbohydrate pellets to chocolate flavored high carbohydrate pellets for the 
remainder of the experiment. This was done because of previous studies that used 
chocolate flavored pellets for operant conditioning studies in rats tested in a binge 
eating model (Smith et al. 2015).  
 
 
Development of chocolate binge-consumption behavior 
The rats were randomly assigned to 3 groups: chocolate exposure group (CE; 
n=15), lab chow exposure group (LChE; n=8), and empty food dish group (n=7). In the 
home cage, a one-day, one-hour exposure to two ceramic dishes took place before the 
introduction of chocolate. The exposure schedule mirrored that used by Vickers et al. 
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(2015), with rats receiving exposure of 1 of 3 different conditions based on their 
assigned group on days 1, 2, 4, 6, 7, 9, 12, 14, 15, 18, 23 and 28. On exposure days, 2 
ceramic dishes were placed in the home cage of each rat for 2 hrs. For the first 
exposures, the chocolate exposure group was given access to one dish containing 
chocolate, and a second, empty dish. Starting on day 7, the chocolate exposure group 
had one dish containing chocolate and another containing lab chow. The lab chow 
exposure group had a dish containing lab chow and one empty dish, and finally, the 
empty food dish group had two empty dishes. After exposure day 28, exposure 
continued on a randomized schedule with 2 sessions happening each week. Starting on 
day 58, the 2 weekly sessions were split between a morning session and an afternoon 
session. Weights of both chocolate and lab chow were taken before and after each 
session.  
 
Administration of Lisdexamfetamine (LDX) during food exposure sessions 
Doses of LDX were based on experiments completed previously (Yohn et al. 
2016b). Starting on week 15 of exposure, IP injections of 0.1875, 0.375, 0.75, 1.5mg/kg 
or vehicle (saline) were given to rats once per week in a randomly varied order 60 
minutes prior to testing. Drug administration only occurred during afternoon exposure 
sessions. Weights of both chocolate and lab chow were taken before and after each 
session to determine the effect of LDX on consumption. 
 
Administration of Lisdexamfetamine during operant behavior sessions 
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Starting on week 20 of exposure, LDX administration of 0.1875, 0.375, 0.75, 
1.5mg/kg or vehicle (saline) was given to rats once per week in a randomly varied order 
60 minutes prior to their operant behavior session. Amount of lever pressing and lab 
chow consumption were both recorded to determine the effect LDX had on both lever 
pressing and chow intake. 
 
Statistical Analyses 
A repeated measures of analysis of variance (ANOVA) was used to evaluate the 
effect of LDX on the amount of chocolate and chow in grams consumed during a food 
intake session. Planned comparisons were used to compare each treatment to the VEH 
group. Effect sizes of consumption amounts were determined using partial eta square 
values. A factorial ANOVA was used to compare the CE group versus the control group 
during the 30-min operant session for both lever pressing (LP) and chow consumption. 
 
Results 
Acquisition of Chocolate Binging Behavior, and Body Weight Data 
 Analysis of the initial acquisition period for chocolate binging behavior was 
performed using a repeated measures ANOVA. There was an overall significant effect 
of binge session [F(11,154) = 27.379, p < 0.001) Fig. 1]. Chocolate intake increased 
dramatically over the first several sessions, leveled off, then decreased slightly when 
chow was introduced. Significant linear [F(1,14) = 89.333, p < 0.001)] and quadratic 
[F(1,14) = 104.153, p < 0.001)] contrasts were seen, leading to separate analyses of the 
sessions before and after chow was introduced. A significant increase across binge 
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sessions was seen before chow was introduced (days 1-7 [F(4,56) = 32.421, p < 0.001]) 
and a small but significant decrease was seen after chow was added to the binge 
sessions (days 9-28 [F(6,84) = 3.892, p = 0.002)]). Repeated measures ANOVA 
analysis of body weights (Figure 2) over the course of the experiment found a significant 
overall effect due to week [F(23, 644) = 195.156, p < 0.001)] but no significant 
difference between the CE and control groups [F(1, 28) = 0.119, p = 0.733)], and no 
interaction (F(1,23) = 0.738, n.s.). This indicated that despite the occasional exposure to 
chocolate, body weight was not affected in the CE group.  
 
Effect of Lisdexamfetamine administration on intake during exposure sessions 
Repeated measures ANOVA showed a significant overall effect of LDX on intake 
of chocolate [F(4,56) = 7.713, p < 0.001) Fig 3.] and lab chow [F(4,56) = 11.475, p < 
0.001 Fig. 3] in the CE group. Planned comparisons analysis found LDX significantly 
reduced chocolate consumption at the highest dose of LDX (p < 0.05) and significantly 
reduced chow consumption at the two highest doses (p < 0.05) when compared to the 
VEH treatment. For the LChE group, the ANOVA approached significance [F(4,28) = 
2.533, 0.05 < p < 0.1) Fig 4.], with a strong tendency towards a decrease in chow intake 
at the highest dose. Table 1 lists the partial eta squared effect sizes for the actions of 
LDX on intake of chocolate and chow across both groups. Moderate to large effect sizes 
for all three ANOVAs illustrate a strong trend towards a reduction of consumption in 
both groups with very large effect sizes (partial eta squared > 0.40) at the highest dose 
of LDX in all three conditions studied. 
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Effect of Lisdexamfetamine administration during operant sessions 
Factorial ANOVA revealed a significant overall effect of LDX treatment on lever 
pressing (PROG/chow choice task) [F(4,112) = 10.739, p < 0.001) Fig. 5], but no 
significant group difference, and no significant treatment x group interaction. For chow 
consumption, there was a significant overall treatment effect [F(4,112) = 5.905, p < 
0.001 Fig. 6]. A group difference was trending towards significance [F(1, 28) = 2.172, p 
= 0.072] but a significant treatment x group interaction [F(1, 28) = 4.561, p < 0.05] was 
seen. Planned comparisons revealed that LDX significantly reduced lever pressing at 
the three highest doses of LDX (p < 0.001) in both groups and significantly reduced 
chow consumption at the three highest doses (p < 0.05, 0.001) of the CE group when 
compared to the VEH treatment. There was no reduction of chow intake in the 
combined control group. 
 
Experiment Two: T-Maze Task 
 The development of novel animal models in the study of motivation are 
necessary in order to continue gaining new insight into this complex aspect of behavior. 
Tasks similar to what was highlighted in experiment one use food as an overall 
motivating factor. Complications using these types of methods can develop when a 
pharmacological agent known to produce appetite suppressing effects is used during 
the task. A question arises about whether or not the observed behavioral outcome is 
due to factors that are specific to the particular motivational stimulus. Running on a 
running wheel (RW) has been shown to be an intrinsically reinforcing activity in rats 
(Kagan and Berkun 1954, Collier and Hirsch 1977, Pierce et al. 1986, Iversen 1993), 
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subject to multiple types of reinforcement schedules. A recent study completed in mice 
found that when given the option to run on a RW or consume freely available lab chow, 
mice consistently chose the RW (Correa et al. 2016). With all of this in mind, in order to 
study the effects of LDX using a task that involved a food reinforcer as well as a non-
food reinforcer, a T-Maze task for rats was developed to pit the desire to consume food 
against the desire for voluntary physical activity in terms of RW activity.  
Using a model similar to what has been developed in mice (Correa et al. 2016), a 
RW was placed in one arm of a standard T-Maze, with a palatable food (Cadbury’s Milk 
Chocolate) placed in a ceramic bowl in the other. Rats were then placed in the middle of 
the maze and given 30 minutes to choose between going back and forth between the 
RW and palatable food. LDX was administered once chocolate consumption and RW 
activity were stable in terms of baseline levels. This new procedure allowing the animal 
to choose between two different motivating factors can be used to tease apart the 
changes in behavior that can become muddied with a single motivating factor. 
 
Methods 
Animals  
Singly-housed, adult female, Wistar rats (N = 8 Charles River) weighing between 
226-250 grams on arrival were given water and food ad libitum. 
 
Development of chocolate binge-consumption behavior: 
 
Similar to the procedure used during the operant experiment, a one-day, one-
hour exposure to a ceramic dish took place in the rat’s home cage before the 
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introduction of chocolate. Rats received exposure of chocolate on days 1, 2, 4, 6, 7, 9, 
12, 14, and 15. On exposure days, 1 ceramic dish was placed in the center front of the 
home cage of each rat for 1 hour. Weight of chocolate was taken before and after each 
session. Amounts given were determined by consumption of the rat in their prior 
session. Once binge-like eating behavior was established, chocolate was no longer 
given in the home cage but was only offered during the T-Maze task. 
 
T-Maze Apparatus 
 A Plexiglas T-maze apparatus consisting of a start arm (29X21X21 cm) and two 
test arms (99X32X59 cm) was utilized for this task. Within the maze, a clear box 
(47.6X25.9X20.9 cm) with a hole (10.3 cm diameter) cut in the front was placed in either 
the right or left arm. This box housed the RW (Starr Life Sciences Corp.) apparatus with 
an attached counter to record RW rotations during sessions. A wall (32X59 cm) with an 
entry hole was placed in front of the box to keep the rats from moving around the box 
during early stages of training. The opposite arm contained a ceramic bowl (9 cm 
diameter) (PetCo) with ground milk chocolate (Cadbury’s Dairy Milk). 
 
 
 
 
T-Maze Training 
RW Training: 
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Rats were first introduced to the RW by being placed directly into the box with the 
entry hole blocked so they only had access to the RW area for two sessions. On the 
third session, the side containing the bowl was blocked off and rats were placed in the 
middle of the maze facing the wall. This required the rat to use the entry hole of the RW 
box. On the final session the maze was open for the rat to explore both arms with an 
empty ceramic bowl placed opposite to the RW. Each session lasted 30 minutes. 
 
Chocolate Training: 
After the induction of chocolate binge behavior, rats were blocked in the arm 
containing the ceramic bowl and chocolate for two sessions. Sessions 3, 4, and 5, of T-
Maze chocolate exposure, the rat was placed in the maze with the RW entry hole 
blocked off, which allowed access to the open maze but entry only to the chocolate arm. 
Each session lasted 30 minutes. 
 
Administration of Lisdexamfetamine (LDX) during T-Maze sessions: 
Doses of LDX were based on experiments completed previously (experiment 
one). Once consistent RW activity and chocolate consumption was reached in the T-
Maze, administration of 0.09375, 0.1875, 0.375, 0.75, 1.5mg/kg or vehicle (saline) was 
given to rats in a randomly varied order once per week, 60 minutes prior to T-Maze 
entry. Weights of chocolate were taken before and after each session, and RW rotations 
(complete rotations) were recorded, to determine the effect LDX had on both chocolate 
intake and RW activity. Video recordings of sessions were used to determine time spent 
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actively or passively interacting with the RW, time spent eating, time spent doing neither 
of those activities, and number of side changes and rears. 
 
Statistical Analyses 
A repeated measures analysis of variance (ANOVA) was used to evaluate the 
acquisition of chocolate binging behavior and the effects of LDX on the percent baseline 
amount of chocolate in grams consumed during a food intake session and percent of 
the averaged weekly baseline RW activity. Planned comparisons were used to compare 
each treatment to the VEH group.  
 
Results 
Acquisition of Chocolate Binging Behavior 
 Analysis of the acquisition period of chocolate binge-like eating behavior (Figure 
7) using a repeated measures ANOVA found an overall significant effect of binge 
session [F(8, 56) = 8.214, p < 0.001)]. A significant linear [F(1, 7) = 16.173, p = 0.005)] 
contrast was seen highlighting the increase in chocolate consumption across sessions. 
 
Effect of LDX administration during T-Maze sessions 
A repeated measures ANOVA of the LDX test sessions in the maze (Figures 8 
and 9) revealed a significant overall effect of LDX treatment on percent baseline 
chocolate consumption [F(5, 35) = 7.879, p < 0.001)], but no significant effect on 
percent baseline RW activity [F(5, 35) = 1.254, p > 0.3]. Planned comparisons revealed 
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that LDX significantly reduced chocolate consumption at all but the lowest dose of LDX 
(p < 0.05) when compared to the VEH treatment.  
 
Discussion 
The overall purpose of these studies was to characterize the effects of the d-
amphetamine pro-drug LDX on intake of chocolate and lab chow, as well as two 
different effort-based choice tasks, one entirely based upon food reinforcement and the 
other comparing two different options (i.e. T-maze choice of RW vs. chocolate intake). 
These studies were done in female rats that were previously exposed to different types 
of food (e.g. chocolate or chow) under conditions that mimic previously used binge-like 
eating models (Vickers et al. 2015). Clinical research shows the prevalence of BED is 
greater in the female population (Dingemans et. al 2002, Kessler et. al 2013, Hutson et. 
al 2018) with twelve-month and life time prevalence rates being 0.8% and 2% in males 
and 1.6% and 3.5% in females respectively (Hudson et al. 2007). Therefore, it was 
deemed important to conduct this research in female rats in order to better mimic what 
is seen in the human population.  
Our results for chocolate binge consumption and body weights from experiment 
one are consistent with what was reported in the literature in studies employing a similar 
rat model (Corwin and Wojnicki 2006, Vickers et al. 2015). Random, intermittent, short 
periods of access of chocolate led to a robust and significant increase in chocolate 
intake over the repeated sessions (Fig. 1). This was attenuated slightly when chow was 
added to the binge sessions and with the removal of food restriction (appendix Fig. 1). 
This attenuation of chow intake was also seen in the LChE group upon the removal of 
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food restriction but in a much larger degree than that in the CE group (appendix Fig. 2). 
The significant increase in body weights for both CE and control animals over the 
course of the study illustrates the natural growth of the rats over time, but there was no 
significant difference in body weights between the CE and control rats, and no 
significant group x week interaction (Figure 2), which is consistent with much of the 
literature on binge-like eating models in rodents (Hagan et al. 2002; Corwin et al. 2011, 
2016; Vickers et al. 2015; Smail-Crevier et al. 2018). In this regard, it is worth 
emphasizing that although BED is more commonly diagnosed in obese individuals, it 
also is seen in individuals within the normal BMI range (Bruce and Wilfley 1996; Hudson 
et al. 2007).  
The d-amphetamine pro-drug LDX became an approved treatment for BED in 
2015. In the case of LDX, d-amphetamine (the active moiety) is covalently bound to the 
amino-acid L-lysine (inactive) via an amide linking group, and the d-amphetamine only 
becomes active once it is metabolized (Heal et. al 2013). This leads to a slow release of 
d-amphetamine and longer lasting effects when compared to d-amphetamine on its 
own. In the clinical setting, LDX has been shown to significantly reduce the number of 
binge eating days/week (McElroy et al. 2016). The results of the present food intake 
studies showed that LDX produced a robust suppression of both chocolate and chow 
intake in the CE group (Fig. 3). There was a trend towards a reduction in lab chow 
intake during the binge sessions in the LChE group (Figure 4), but due to a small 
sample size (n=7) this effect did not reach statistical significance. Nevertheless, it can 
also be seen in Table 1 that the effect size for the action of LDX in the LChE group was 
quite large, and roughly comparable to that seen in the CE group.  
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In terms of results from the operant experiment, there was an overall significant 
reduction of lever pressing induced by LDX that was seen across both groups. There 
was an overall significant effect of LDX on chow intake, however, there also was a 
significant group x drug treatment interaction.  It appears that a major source of the 
interaction was due to the high consumption of chow in the CE group compared to the 
control group after VEH treatment. This difference allowed for a significant reduction in 
lab chow consumption in the CE group, but there may not have been a significant 
reduction in the control group due to a floor effect. Given this pattern of results, it is 
reasonable to suggest that with the induction of the binging behavior in the CE group, 
these animals also consumed more chow during the operant sessions compared to the 
control group, and that this led them to be more sensitive to the effects of LDX in that 
setting.  
It is important to point out that these drug studies were performed under 
conditions in which the animals were not food restricted. Food restriction is generally 
useful in order to have rats emit large numbers of responses for food reinforcement. 
Thus, food restriction was used during the initial portion of the operant training. 
However, it was decided to remove the rats from food restriction after initial acquisition 
in order to better mimic what is seen clinically in people with BED, as well as in other rat 
models of binging behavior. Once food restriction was removed, we observed lower 
levels of both lever pressing and food intake in the rats (appendix Figs. 3 & 4). It is 
possible that more robust results in the operant study would have been seen if the rats 
had continued on food restriction. 
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The induction of the binge-like consumption of chocolate in the T-maze study 
varied slightly from what was seen in the operant task. This was due to the fact that 
once the T-Maze task was underway, rats only received chocolate in the maze. The rats 
completing the RW task were also not food restricted at any point of the study. Even 
with these variations from the protocol in experiment one, a robust increase in chocolate 
intake was seen (Fig. 7) with the use of random, intermittent, short periods of access to 
chocolate. This finding adds to the already established literature that food restriction is 
not an important factor in the development of binging behavior in animal models (Avena 
et al. 2006; Corwin & Wojnicki 2006), and also what is seen in the BED human 
population, with whom hunger is not always a driving factor of binging episodes 
(Brownley, Berkman, Sedway, Lohr, & Bulik, 2007; Davis et al., 2007). 
The purpose of developing a novel task that pits two reinforcing behaviors 
against one another was intended to clarify some of the factors mediating the actions of 
LDX. Due to the appetite suppressant effects previously mentioned, it becomes difficult 
to say the results we observed in the operant task, which is an entirely food motivated 
task, are not simply due to the fact the rat is no longer hungry. The results from the RW 
task showed a similar pattern of chocolate intake seen in both the strict binge 
consumption and operant tasks of experiment one, with a significant reduction of intake 
in a dose dependent manner (Fig. 8). Percent of baseline analyses were used due to 
the fact that the rats varied greatly from one another in their intakes. It was not 
surprising that there was a reduction in intake of chocolate given the results of 
experiment one and the previously mentioned literature on LDX’s ability to attenuate 
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binging behaviors in both rat models and human participants (Hagan et al. 2002; Corwin 
et al. 2011, 2016; Vickers et al. 2015; Smail-Crevier et al. 2018; McElroy et al. 2016). 
Amphetamine exposure induces differential alterations across multiple activities 
based on the baseline level of behavior and the dose given. Rate-dependency is a drug-
induced change in operant behavior in which schedules of reinforcement with high rates 
of responding will yield decreases in responding with the administration of a stimulant, 
while those with low baseline rates tend to increase (Dews 1958). RW activity was high 
in this group of rats, with an average of 252+ 6.33 rotations of the RW in 30 minutes. 
Lyon and Robbins (1978) highlighted the fact that different doses of psychomotor 
stimulants elicit different behavior with low doses producing an increase switching from 
one thing to another with high doses resulting in perseveration and stereotypy. LDX 
administration had no significant effect on RW activity but there was a trend towards a 
reduction of activity as doses of LDX increased (Fig. 9). Due to the high activity prior to 
drug exposure, it appears this task may be subject to rate-dependent effects, and it is 
also possible that, with the increasing doses of LDX, rats began engaging in other 
behaviors (i.e. increased exploration of maze, rearing, etc.) that lead to a decrease in 
the amount of RW activity. Serwatkiewicz at al. (2000) found a similar phenomenon with 
rats exposed to d-amphetamine. They found a significant decrease in RW activity at the 
highest doses of d-amphetamine administered, and concluded that this was due to an 
increase of stereotypic behavior. It is likely that with a higher N, the reduction in RW 
activity would have been found to be significant.  
Overall, it is clear that LDX reduces intake of the highly palatable chocolate. 
However, it also seems evident that the effect of LDX is not limited to chocolate 
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consumption. Thus, a part of the effect of LDX appears to be a general suppression of 
food intake, as indicated by the reductions in chow intake that also were seen in 
experiment one.  Moreover, LDX suppressed food-reinforced PROG responding across 
both the chocolate exposure and control groups. Comparing this with the results seen in 
the T-Maze task, this reduction in lever pressing could also be attributed to an increase 
in alternative activities, similar to the decrease in RW activity seen in experiment two. 
Previous studies have shown that LDX suppresses chow intake in rats in the context of 
studies using binge-like eating procedures (Vickers et al., 2015), although this point was 
not highly emphasized in that paper. The active moiety in LDX, d-amphetamine, has 
been shown to induce appetite suppressant effects, thus leading to its use as a weight 
loss drug for several decades (Coleman 2005).  This is consistent with the fact that a 
general suppression of appetite has been reported as a side effect of using LDX to treat 
BED in humans (Citrome 2015, McElroy et al. 2016; Ward and Citrome 2018).  
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Fig. 1. Chocolate and Chow intakes for CE group over the course of acquisition of binge 
eating behavior (Mean + SEM intake in grams). Coinciding with introduction to lab chow 
during operant task, chow was introduced during 6th binge session. An increase in 
chocolate intake was seen before the addition of chow at which put intake was slightly 
reduced. 
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Fig. 2. Weights of CE and control animals (Mean + SEM body weight in grams) during a 
24-week period. Both groups showed steady increases in weight with a significant 
overall effect due to week but no significant weight difference between groups, or group 
x week interaction. 
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Fig. 3. The effects of LDX on chocolate and chow consumption in the CE group during 
the 120-minute binge session. Rats (n = 15) received IP injections of vehicle (VEH), 
0.1875, 0.375, 0.75, and 1.5 mg/kg doses of LDX. Mean (+ SEM) chocolate or chow 
consumption (in grams) during 120-minute binge session shown. LDX dose significantly 
different from VEH for chow, *p < 0.05; LDX dose significantly different from VEH for 
chocolate, # p < 0.05. 
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Fig. 4. The effects of LDX on chow consumption in the LChE group during the 120-
minute binge session. Rats (n = 8) received IP injections of vehicle (VEH), 0.1875, 
0.375, 0.75, and 1.5 mg/kg doses of LDX. Mean (+-SEM) chow consumption (in grams) 
during 120-minute binge session shown. + LDX dose approached difference from VEH, 
0.05 > p < 0.1. 
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Fig. 5. The effects of LDX on lever pressing in the CE and control groups during the 30-
minute operant session. Rats (n = 30) received IP injections of vehicle (VEH), 0.1875, 
0.375, 0.75, and 1.5 mg/kg doses of LDX. Mean (+ SEM) number of lever presses 
during 30-minute operant session (PROG/chow choice) shown. LDX dose significantly 
different from VEH, **p < 0.001. 
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Fig. 6. The effects of LDX on chow consumption in the CE and control groups during 
the 30-minute operant session. Rats (n = 30) received IP injections of vehicle (VEH), 
0.1875, 0.375, 0.75, and 1.5 mg/kg doses of LDX. Mean (+ SEM) consumption of chow 
during 30-minute operant session (PROG/chow choice) shown. LDX dose significantly 
different from VEH, *p < 0.05, **p < 0.001. Significant dose by group interaction # p < 
0.05. Difference between groups +0.05 < p < 0.1.  
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Fig. 7. Chocolate intake for T-Maze group over the course of acquisition of binge eating 
behavior (Mean + SEM intake in grams). An increase in chocolate intake was seen over 
the course of exposure. 
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Fig. 8. The effects of LDX on the percentage of averaged 3 day baseline of chocolate 
consumption. Rats (n = 8) received IP injections of vehicle (VEH), 0.09375, 0.1875, 
0.375, 0.75, and 1.5 mg/kg doses of LDX. Mean of percent baseline (+ SEM) 
consumption of chocolate during 30-minute T-Maze session shown. LDX dose 
significantly different from VEH, *p < 0.05, **p < 0.01, ***p < 0.001.  
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Fig. 9. The effects of LDX on the percentage of averaged 3 day baseline of RW activity. 
Rats (n = 8) received IP injections of vehicle (VEH), 0.09375, 0.1875, 0.375, 0.75, and 
1.5 mg/kg doses of LDX. Mean of percent baseline (+ SEM) RW activity determined 
through RW rotations during 30-minute T-Maze session shown.  There was a trend 
towards a decrease in RW activity by LDX in a dose dependent manner. 
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Appendix Fig 1. Chocolate and Chow intakes for CE group over the course of 26 binge 
sessions. Coinciding with introduction to lab chow during operant task, chow was 
introduced during 6th binge session. An intake of both foods was reduced once non-food 
restriction began. 
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Appendix Fig 2. Chow intake reduced after non-food restriction for both CE and LChE 
groups during binge eating sessions.  
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Appendix Fig 3. Weekly average lever pressing for both CE and control groups during 
30 minute PROG ratio/feeding task throughout a 20-week period. Groups were food 
restricted during Weeks 1-6 and non-food restricted Weeks 7-20. Concurrently available 
lab chow was introduced at the start of Week 2. Reward was plain high carbohydrate 
pellets weeks 1-11 and chocolate flavored weeks 12-20.  
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Appendix Fig 4. Chow intake during operant session for both CE and control groups 
during 30 minute PROG ratio/feeding task throughout a 20-week period. Groups were 
food restricted during Weeks 1-6 and non-food restricted Weeks 7-20.  Shifting from 
food restriction to non-food restriction decreased chow intake in both groups. 
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